ClinicalTrials.gg
RecruitingNCT04008121Updated Feb 4, 2026

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

An Early Phase 1 interventional study of Fluorescein sodium and Zeiss FF450 fundus camera and MB-102 and Zeiss FF450 fundus camera in Retinopathy, Retinal Vein Occlusion and Diabetic Retinopathy, sponsored by MediBeacon. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by MediBeacon · Early Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.

Planned enrollment
85th of 111
10 · median 36
Started
2025
with 6 others
Phase 1
20 of 162
2 open now
Primary completion
2026-12
later than 9 of 37 live
Registered
88th of 162
by date

Among the 162 studies in Retinal Diseases with a site in United States, this one is the 85th largest by planned enrollment of the 111 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 9 of the 37 other live ones, and was the 88th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 60 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Retinal Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.

Read the detailed description

This will be a single-dose study, in normal participants and in those with current retinal pathology, investigating feasibility of the investigational dye, MB-102, for use in fluorescent angiography compared to fluorescein sodium. Safety and tolerability of MB-102 will also be evaluated. Control dye fluorescein sodium will be administered intravenously a minimum of 3 days prior to MB-102 dosing. After IV administration of dyes, images will be acquired of both eyes with a Zeiss fundus camera (and for some participants additional fundus photography will be performed with clinically-approved ocular angiography imaging systems) by a trained ophthalmic photographer. Participants will return for a follow-up visit after MB-102 dosing for further physical examination, clinical laboratory tests, and reporting of any adverse events. Photographs will be examined for quality as well as the utility of the angiography in evaluating disease diagnosis and progression.

03

Conditions studied

  • Retinopathy
  • Retinal Vein Occlusion
  • Diabetic Retinopathy
  • Macular Degeneration

Keywords

  • Fluorescein angiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years - male or female

    1. Eligible female non-pregnant participants who are either not of or willing to utilize adequate during the trial
    2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose
  • Participants willing to comply with study requirements
  • Participants who have signed an form

At least 5 participants will have a current history of retinal or choroidal vascular diseases.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of unwilling to utilize adequate
  • Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study
  • History of drug or alcohol abuse within the past year
  • History of severe allergic reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).
  • Prior history of seizures
  • Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs
  • Site personnel immediately associated with the study or their immediate family members
  • Unable to tolerate ophthalmologic imaging
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered or unstable by the Principal Investigator)
  • Prior enrollment and dosing in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Adult participants with normal or diseased eyes

    500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography

    Combination Product: Fluorescein sodium and Zeiss FF450 fundus camera · Combination Product: MB-102 and Zeiss FF450 fundus camera · Combination Product: Fluorescein sodium and commercially available optical angiography imaging system · Combination Product: MB-102 and commercially available optical angiography imaging system

Interventions

  • Combination productFluorescein sodium and Zeiss FF450 fundus camera

    Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants

  • Combination productMB-102 and Zeiss FF450 fundus camera

    MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants

  • Combination productFluorescein sodium and commercially available optical angiography imaging system

    Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants

  • Combination productMB-102 and commercially available optical angiography imaging system

    Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants

06

What researchers measure

Primary outcomes

  1. Binary assessment by the Principal Investigator of the feasibility of MB-102 imaging as compared to fluorescein dye

    Ocular angiography will be performed using a commercially available, FDA-approved clinical Zeiss FF450 fundus camera. Images will be taken of both eyes, acquired by a trained ophthalmic photographer. In at least 2 participants, imaging will also be conducted using 2 different additional clinically-approved ocular angiography imaging systems.

    Time frame: From the time of fluorescein sodium administration through optical angiography study completion, up to 2 weeks

Secondary outcomes

  1. Number of participants with adverse events

    An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, temporally associated with the use of a medicinal product, whether or not related to the investigational drug or the reference medication. Adverse events will be collected from the time a participant is considered enrolled (after consent is signed) through the follow-up visit. Participants who fail screening will not have AEs collected.

    Time frame: From the time of study enrollment until the end of adverse event collection, up to 24 days

07

Study locations

1 of 1 sites recruiting
  • University of Michigan Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Julie M Rosenthal, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
Jul 5, 2019
StartActual
Nov 6, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04008121
Lead sponsor
MediBeacon
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Nov 6, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Richard B Dorshow, PhD
Contact
rbdorshow@medibeacon.com
314-735-0967
Richard B Dorshow, PhD
study director · MediBeacon

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion